Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Corotrop
2. Corotrope
3. Lactate, Milrinone
4. Milrinone
5. Primacor
6. Win 47203
7. Win-47203
8. Win47203
1. 100286-97-3
2. 9k8xr81mo8
3. 6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile Lactate
4. 2-hydroxypropanoic Acid;6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile
5. Chebi:34850
6. Unii-9k8xr81mo8
7. Milrinonelactate
8. Milrinone Lactose In 5% Dextrose
9. Primacor (tn)
10. Primacor In Dextrose 5% In Plastic Container
11. Milrinone Lactate [mi]
12. Milrinone Lactate In 5% Dextrose In Plastic Container
13. Chembl1200977
14. Milrinone Lactate [vandf]
15. Milrinone Lactate [mart.]
16. Milrinone Lactate In Dextrose 5% In Plastic Container
17. Milrinone Lactate [who-dd]
18. Akos015917733
19. Milrinone Lactate [orange Book]
20. 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile, Compd. With 2-hydroxypropionic Acid
21. Ls-14389
22. Ft-0739660
23. D02085
24. 286m973
25. A897507
26. Q27116295
27. 2-[(4-chlorobenzyl)sulfanyl]benzenecarboxylicacid
28. 1,6-dihydro-2-methyl-6-oxo[3,4'-bipyridine]-5-carbonitrile Lactate
29. 2-hydroxypropanoic Acid,6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile
30. 6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile 2-hydroxypropanoic Acid
31. Hydron;2-hydroxypropanoate;6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile
32. Propanoic Acid, 2-hydroxy-, Compd. With 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
Molecular Weight | 301.30 g/mol |
---|---|
Molecular Formula | C15H15N3O4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 301.10625597 g/mol |
Monoisotopic Mass | 301.10625597 g/mol |
Topological Polar Surface Area | 123 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 478 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Milrinone lactate |
Drug Label | Milrinone Lactate Injection is a member of a new class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-Dihyd... |
Active Ingredient | Milrinone lactate |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/20ml; eq 1mg base/ml; eq 20mg /20ml (1mg/ml); eq 50mg /50ml (1mg/ml) |
Market Status | Prescription |
Company | Bedford; Hospira; Gland Pharma; Apotex; Hikma Farmaceutica; Fresenius Kabi Usa; Hikma Maple; Intl Medicated |
2 of 2 | |
---|---|
Drug Name | Milrinone lactate |
Drug Label | Milrinone Lactate Injection is a member of a new class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-Dihyd... |
Active Ingredient | Milrinone lactate |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/20ml; eq 1mg base/ml; eq 20mg /20ml (1mg/ml); eq 50mg /50ml (1mg/ml) |
Market Status | Prescription |
Company | Bedford; Hospira; Gland Pharma; Apotex; Hikma Farmaceutica; Fresenius Kabi Usa; Hikma Maple; Intl Medicated |
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Phosphodiesterase 3 Inhibitors
Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Milrinone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Milrinone, including repackagers and relabelers. The FDA regulates Milrinone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Milrinone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Milrinone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Milrinone supplier is an individual or a company that provides Milrinone active pharmaceutical ingredient (API) or Milrinone finished formulations upon request. The Milrinone suppliers may include Milrinone API manufacturers, exporters, distributors and traders.
click here to find a list of Milrinone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Milrinone DMF (Drug Master File) is a document detailing the whole manufacturing process of Milrinone active pharmaceutical ingredient (API) in detail. Different forms of Milrinone DMFs exist exist since differing nations have different regulations, such as Milrinone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Milrinone DMF submitted to regulatory agencies in the US is known as a USDMF. Milrinone USDMF includes data on Milrinone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Milrinone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Milrinone suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Milrinone Drug Master File in Japan (Milrinone JDMF) empowers Milrinone API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Milrinone JDMF during the approval evaluation for pharmaceutical products. At the time of Milrinone JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Milrinone suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Milrinone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Milrinone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Milrinone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Milrinone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Milrinone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Milrinone suppliers with NDC on PharmaCompass.
Milrinone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Milrinone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Milrinone GMP manufacturer or Milrinone GMP API supplier for your needs.
A Milrinone CoA (Certificate of Analysis) is a formal document that attests to Milrinone's compliance with Milrinone specifications and serves as a tool for batch-level quality control.
Milrinone CoA mostly includes findings from lab analyses of a specific batch. For each Milrinone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Milrinone may be tested according to a variety of international standards, such as European Pharmacopoeia (Milrinone EP), Milrinone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Milrinone USP).
LOOKING FOR A SUPPLIER?